# Neurovisceral Syndrome in a Patient with Monoclonal Gammopathy of Undetermined Significance: A Confirmed Case of Variegate Porphyria

**Authors:** Iraj Fatima, Kashaf ad Duja Awais, Aasim Sehbai, Ali Awais Khan Tareen, Maheen Shaharyar

PMC · DOI: 10.7759/cureus.92741 · Cureus · 2025-09-19

## TL;DR

A 53-year-old man with a rare condition called variegate porphyria was misdiagnosed for months before receiving the correct diagnosis and effective treatment.

## Contribution

This paper presents a confirmed case of variegate porphyria coexisting with monoclonal gammopathy and highlights the use of enzyme-targeting therapy.

## Key findings

- The patient was diagnosed with variegate porphyria after multiple misdiagnoses and extensive testing.
- Treatment with Givosiran effectively controlled symptoms when hemin therapy caused complications.
- The case emphasizes the importance of considering rare metabolic disorders in complex clinical presentations.

## Abstract

Variegate porphyria (VP) is a rare disorder presenting with cutaneous, neurological, and systemic symptoms. We report a 53-year-old man initially hospitalized for a depressive episode, during which blistering lesions and facial flushing were noted. He was misdiagnosed and treated for cellulitis and contact dermatitis without improvement. Repeated misdiagnoses led to extensive autoimmune, infectious, and hematologic workup, revealing coexisting monoclonal gammopathy of undetermined significance (MGUS). Over the following months, he developed abdominal pain, mood swings, cognitive impairment, neuropathy, orthostatic symptoms, and weight loss, raising suspicion for porphyria. A 24-hour urine panel revealed elevated porphobilinogen (PBG), delta-aminolevulinic acid (ALA), coproporphyrin I and III, heptacarboxyl porphyrins, and mildly elevated uroporphyrins, confirming VP. Treatment with hemin caused thrombophlebitis and was discontinued. He was transitioned to Givosiran, resulting in symptom control and no further flares. This case reinforces the need to consider rare metabolic disorders in unexplained multisystem presentations and highlights the role of enzyme-targeting therapy when conventional treatment is not tolerated.

## Linked entities

- **Chemicals:** hemin (PubChem CID 26945), porphobilinogen (PubChem CID 1021), delta-aminolevulinic acid (PubChem CID 137), coproporphyrin I (PubChem CID 68271), coproporphyrin III (PubChem CID 114935)
- **Diseases:** variegate porphyria (MONDO:0008297), monoclonal gammopathy of undetermined significance (MONDO:0004225), cellulitis (MONDO:0005230), contact dermatitis (MONDO:0005480)

## Full-text entities

- **Diseases:** MGUS (MESH:D008998), orthostatic symptoms (MESH:D006261), weight loss (MESH:D015431), thrombophlebitis (MESH:D013924), abdominal pain (MESH:D015746), porphyria (MESH:D011164), contact dermatitis (MESH:D003877), neuropathy (MESH:D009422), cellulitis (MESH:D002481), cognitive impairment (MESH:D003072), VP (MESH:D046350), depressive (MESH:D003866), metabolic disorders (MESH:D008659), Neurovisceral Syndrome (MESH:D052536), facial flushing (MESH:D005483)
- **Chemicals:** ALA (MESH:D000622), PBG (MESH:D011162), Givosiran (MESH:C000630124), hemin (MESH:D006427), uroporphyrins (MESH:D014578), heptacarboxyl porphyrins (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12538662/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12538662/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12538662/full.md

---
Source: https://tomesphere.com/paper/PMC12538662